Table 1 Baseline characteristics of included patients (n = 32).

From: Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients

Characteristics

Median

Range (min–max)

Age (yr)

52

20–70

Sex (male)a

20

63%

Weight (kg)

62.7

43.9–102.4

Height (cm)

165.8

151–180

Hemoglobin (g/dL)

14.1

10.6–17.5

Hematocrit (%)

43.6

32.3–53.8

Serum creatinine (mg/dL)

1.22

0.69–1.66

MDRD eGFR (mL/min/1.73 m2)

59.5

35.0–85.7

Albumin (g/dL)

4.4

3.8–5.0

Total bilirubin (mg/dL)

0.7

0.5–2.4

Tacrolimus daily dose (mg)

2

1–6

Mycophenolate mofetil daily dose (mg)

1,000

500–2,000

Prednisolone daily dose (mg)b

5

2.5–5

Post-operative days (yr)

5.7

0.6–10.4

Collected blood samples per patients

4

1–5

CYP3A5 (rs776746) expressera

13

40.6%

SLCO1B3 (rs4149117) T carriera

15

46.9%

UGT2B7 (rs7439366) T carriera

15

46.9%

  1. aSex and CYP3A5 expresser are presented as number and proportion; bPrednisolone or its equivalent; CYP3A5 expresser, CYP3A5 *1/*1 or CYP3A5 *1/*3 carriers; MDRD, modification of diet in renal disease; eGFR, estimated glomerular filtration rate.
Back to article page